Navigation Links
DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
Date:5/2/2013

lude, but are not limited to, the risk that Pfizer will discontinue development of REMOXY, the risk of adverse decisions by regulatory agencies, including requests for additional information or product non-approval or non-acceptance of our POSIDUR or other NDA submissions, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet their intended endpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and risks related to our (and our third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to our development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of product candidates, manufacture and commercialize product candidates, obtain marketplace acceptance of product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K for the fiscal year ending on December 31, 2012 under the heading "Risk Factors."

 

 DURECT CORPORATION CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (in thousands, except per share amounts) (Unaudited)Three months ended March 31, 20132012Collaborative research and development and other revenue

$
913$38,328Product revenue, net

3,2402,857Total revenues

4,15341,185Operating expenses:Cost of product revenues 

1,6581,461Research and development

4,7895,634Selling, general and administrative 

2,9013,280Total operating ex
'/>"/>

SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
2. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
3. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
4. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
5. DURECT to Participate in Upcoming Healthcare Conferences
6. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
7. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
8. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
9. Luminex Corporation Reports First Quarter 2013 Results
10. Comprehensive Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
11. Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Ore. and NEPTUNE, N.J., Jan. 11, 2012 /PRNewswire-iReach/ ... patients to easily record their pain levels before and ... available, useful, patient information.  The Health Journal for Pain ... stamp pain levels and the impact of both long-acting ...
...  MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... and bioimplants processed from human amniotic membrane, announced ... Capital Markets 8th Annual Equity Conference in Hollywood, ... William C. Taylor, President and COO and Michael ...
Cached Medicine Technology:HealthSaaS Inc. with iMPak Health and Meridian Health Announce Integrated Pain Management and Medication Adherence Solution 2HealthSaaS Inc. with iMPak Health and Meridian Health Announce Integrated Pain Management and Medication Adherence Solution 3
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... 11, 2014 The report “Probiotics ... Nutrients, Animal Feed), Applications (Regular, Therapeutic, Preventive Health ... Trends & Forecasts to 2019 ” defines and ... and forecasting of the market value of probiotic ... driving and restraining factors for the global market ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Presently, disposable ... overall healthcare equipment and supplies segment. During the past ... witnessed steady growth (on an average 12.5% per year), ... healthcare settings. Currently, the US is the largest market ... a share of 40%. The second position is held ...
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 The ... the five years to 2014 on the heels of ... 2010 prompted farmers to dedicate a larger share of ... production. More specifically, the regulations required the mixing of ... expanding biofuel production in the United States created a ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... live with diabetes across the world and 4.4 million ... control can lead to devastating complications, like blood vessel ... cause 85% of all amputations. , The Faculty of ... of Rotary International has just received a grant for ...
... and medical staff can now be on the same ... EnglishSpanish (Una Gua Para el Paciente Sobre Procedimientos de ... Written in both English and Spanish, the book explains ... the patient can expect prior to and during more ...
... Baxa Corporation announces,the latest addition to its ... offerings. Safe Handling and Preparation of Hazardous ... physicians that prepare,handle or administer hazardous drugs. ... compliance and industry best practice to provide,the ...
... Angiography plus anti-clotting drug keep tissue viable, researchers say ... treatment can help save severely frostbitten limbs that might ... severe frostbite, deep tissue freezing can damage muscles, tendons, ... limb amputation, according to background information in the study. ...
... 24, 2008 -- Share ... name change to Hill-Rom Holdings, Inc., at separation; recently created Batesville ... and "When Issued" Trading expected to commence March ... 19, 2008, ...
... RALEIGH, N.C., March 17 Randy Jackson, music ... to help raise awareness,among the local community about ... (CVD). Jackson partnered with the American Heart,Association to ... Heart of,Diabetes(TM), to help those living with type ...
Cached Medicine News:Health News:Egyptian foot care center recieves International Diabetes Federation grant 2Health News:Flip-chart book translates complicated medical procedures into easy-to-understand language 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 3Health News:Therapy Could Save Limbs After Frostbite 2Health News:Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 2Health News:Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 3Health News:Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 4Health News:Randy Jackson and the American Heart Association Educate Raleigh Area Residents About the Connection Between Type 2 Diabetes and Cardiovascular Disease 2Health News:Randy Jackson and the American Heart Association Educate Raleigh Area Residents About the Connection Between Type 2 Diabetes and Cardiovascular Disease 3
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
Dual laser powered flow cytometer...
... The IMMULITE 2000, a continuous ... throughput of 200 tests per hour, ... efficiency and consolidation in medium- and ... package, with its self-explanatory graphical user ...
... Vidas is an automated, ... designed testing device stores the ... thus optimizing the cost-per-patient result. ... minimum maintenance, ease of use ...
Medicine Products: